TREATMENT OF EXPERIMENTAL LISTERIOSIS BY CI-934, A NEW QUINOLONE

CI 934, a new quinolone, is only marginally more active in vitro against Listeria monocytogenes and other Listeria spp. than ciprofloxacin. A bactericidal effect is seen only after several hours of incubation. However, mice infected with a virulent strain of L. monocytogenes were protected by parenteral treatment with CI 934. With a dosage of 2 × 2 mg CI 934 per day for three days almost complete remission could be achieved. These results are somewhat better than those obtained in previous experiments with other antibiotics. © 1990 The British Society for Antimicrobial Chemotherapy.